- 1 U.S. FOOD AND DRUG ADMINISTRATION: Statement on improving adverse event reporting of compounded drugs to protect patients
- 2 HORIZON THERAPEUTICS PLC: Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)
- 3 RIDGEBACK BIOTHERAPEUTICS LP: Announces receipt of Breakthrough Therapy designation from FDA for mAb114
- 4 New legislation proposed to regulate Pennsylvania CBD and kratom sales
- 5 FDA creating new labeling guidelines for opioid medications
Get the latest business news and updates - delivered right to your inbox
By signing up you agree to receive email newsletters or alerts from FDA Reporter. You can unsubscribe at any time.